A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer Article

cited authors

  • Donin, Nicholas M.; Chamie, Karim; Lenis, Andrew T.; Pantuck, Allan J.; Reddy, Madhu; Kivlin, Dana; Holldack, Johanna; Pozzi, Rafaella; Hakim, Gil; Karsh, Lawrence I.; Lamm, Donald L.; Belkoff, Laurence H.; Belldegrun, Arie S.; Holden, Stuart; Shore, Neal

authors

Publication Date

  • February 1, 2017

webpage

published in

category

keywords

  • Administrations
  • Carcinoma in situ
  • Imiquimod
  • Immunotherapy
  • Urinary bladder neoplasms
  • intravesical drug

volume

  • 35

issue

  • 2